^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)

    i
    Other names: IKBKE, Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon, Inhibitor Of Kappa Light Polypeptide Gene Enhancer In B-Cells Kinase Epsilon, Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Epsilon, Inducible I Kappa-B Kinase, I-Kappa-B Kinase Epsilon, IKK-Epsilon, IKK-E, IKK-I, IKKE, IKKI, IKK-Related Kinase Epsilon, Inducible IkappaB Kinase, KIAA0151, IkBKE
    18d
    Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer. (PubMed, Proc Natl Acad Sci U S A)
    Here, we evaluated targeting candidates from this signature KMT5B/C and IKBKE using inhibitors A-196 and IKBKEi respectively, alongside anti-estrogen (fulvestrant) and a TGFβ blocking antibody (NIS793), both individually and in combination with αPD-L1, within this rat model. Comprehensive tumor profiling through polychromatic flow cytometry and single-cell RNA sequencing revealed that A-196 induced a luminal-to-basal shift in tumor epithelial cells, enhancing antigen presentation, whereas epithelial-to-mesenchymal transition was linked to fulvestrant resistance. Our findings underscore the value of the rat mammary tumor model for preclinical studies in ER-positive breast cancer and advocate for the further validation and potential clinical development of KMT5B/C inhibitors to enhance the efficacy and broaden the applicability of ICI therapy in cancer patients.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • TGFB1 (Transforming Growth Factor Beta 1) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    |
    ER positive • HR positive
    |
    fulvestrant • nisevokitug (NIS793)
    19d
    Pre-clinical Evaluation of Shilajit in Cancer: A Systematic Review. (PubMed, Cureus)
    This evidence is preclinical, and standardization issues restrict clinical translation. The results support continued investigation through rigorous, blinded studies, recognising that no clinical trials currently exist and that any potential clinical translation remains speculative at this stage.
    Preclinical • Review • Journal
    |
    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    1m
    CXCL14 Promotes Ovarian Cancer Progression and Autophagy Through the IKBKE/NF-κB Pathway. (PubMed, J Gene Med)
    In vivo, CXCL14 overexpression markedly enhances ovarian tumor growth, accompanied by increased levels of IKBKE and phosphorylated p65. These findings elucidate a novel regulatory axis, CXCL14/IKBKE/NF-κB, in ovarian cancer progression, highlighting CXCL14 as a potential therapeutic target for ovarian cancer treatment.
    Journal
    |
    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • NFKBIA (NFKB Inhibitor Alpha 2) • CXCL14 (C-X-C Motif Chemokine Ligand 14)
    1m
    Reversing enhancer RNA-mediated IKBKE gene repression enables synthetic anticancer immunity in prostate cancer models. (PubMed, J Clin Invest)
    IKBKE-e ablation largely enhanced innate immunity in prostate cancer cells in culture and anticancer immunity in mice. Our results revealed AR, HDAC2, and IKBKE eRNA as critical intrinsic immune suppressors in prostate cancer cells, suggesting that rejuvenating inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKKε) signaling by targeting IKBKE-e is an actionable strategy to elicit synthetic anticancer immunity in immunologically "cold" cancers such as prostate cancer.
    Preclinical • Journal
    |
    HDAC2 (Histone deacetylase 2) • IFIH1 (Interferon Induced With Helicase C Domain 1) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    1m
    NCI-2017-02296: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (clinicaltrials.gov)
    P2, N=60, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ABL1 (ABL proto-oncogene 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • STK11 (Serine/threonine kinase 11) • NPM1 (Nucleophosmin 1) • POLE (DNA Polymerase Epsilon) • CCND1 (Cyclin D1) • BAP1 (BRCA1 Associated Protein 1) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • POLD1 (DNA Polymerase Delta 1) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • BRD4 (Bromodomain Containing 4) • DOT1L (DOT1 Like Histone Lysine Methyltransferase) • FANCE (FA Complementation Group E) • FANCG (FA Complementation Group G) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • FANCC (FA Complementation Group C)
    |
    PALB2 mutation • BRIP1 mutation
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx
    |
    Lynparza (olaparib)
    2ms
    Exploration of the Prognostic Role of Apoptosis-Related Genes in Glioblastoma. (PubMed, Stem Cells Int)
    An apoptosis-related gene prognostic model (AS model) with high predictive performance was constructed and had close associations with the tumor immune microenvironment and intercellular communication. The HSPB1 had a good predictive effect on GBM prognosis.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • CHEK2 (Checkpoint kinase 2) • HSPB1 (Heat shock 27kDa protein 1) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • SMYD3 (SET And MYND Domain Containing 3) • MAPK8 (Mitogen-activated protein kinase 8)
    2ms
    Unveiling the therapeutic potential and leukemia risk of PD-166866 in sepsis via an integrated computational-experimental strategy. (PubMed, Toxicol Appl Pharmacol)
    This study confirms that PD-166866 exerts anti-sepsis effects by regulating pathways such as Rap1, but it also has the potential risk of inducing leukemia. More importantly, this study successfully established a comprehensive evaluation framework integrating in silico and in vitro experiments. It provides a feasible methodological reference for systematically evaluating the dual attributes of "efficacy-risk" in the early stage of drug development and reducing the initial reliance on traditional animal models.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CCND1 (Cyclin D1) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    2ms
    IKBKE modulates autophagy and progestin resistance in endometrial cancer. (PubMed, Front Oncol)
    A progestin-resistant EC cell line was established to assess the effects of IKBKE knockdown and treatment with CYT387, a selective IKBKE inhibitor...These findings highlight the crucial role of IKBKE in regulating autophagy and mediating progestin resistance in EC. This study provides new insights into IKBKE as a potential molecular target that contributes to understanding the mechanisms underlying progestin resistance in endometrial cancer.
    Journal
    |
    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    |
    Ojjaara (momelotinib)
    3ms
    Picornavirus VP2 protein suppresses innate immunity through selective autophagic degradation of IKBKE/IKKε. (PubMed, Autophagy)
    These data elucidate the negative regulatory mechanism involving the VP2-RNF114-IKBKE/IKKε-CALCOCO2 axis, and reveal an immune evasion strategy employed by picornaviruses. These findings will provide valuable insights for the development of picornaviral vaccines and antiviral/antitumor therapeutics.
    Journal
    |
    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • RNF114 (Ring Finger Protein 114)
    4ms
    Comprehensive molecular analysis of uveal melanoma identifies targets in tumor-intrinsic and tumor-extrinsic pathways. (PubMed, iScience)
    In high-risk BRCA1-associated protein 1 (BAP1)-negative tumors, T cell function and tumor necrosis factor (TNF) superfamily genes were downregulated, indicating immune evasion. These findings underscore ANGPTL4, STAT3, and TNFRSF14 as potential biomarkers and drug targets, emphasizing the need to address tumor-intrinsic and tumor-extrinsic pathways to improve treatment strategies.
    Journal • BRCA Biomarker
    |
    BAP1 (BRCA1 Associated Protein 1) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TNFRSF14 (TNF Receptor Superfamily Member 14) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    7ms
    Crebanine Induces Cell Death and Alters the Mitotic Process in Renal Cell Carcinoma In Vitro. (PubMed, Int J Mol Sci)
    Finally, the expressions of G1/S phase transition cyclin D1, cyclin E/CDK2, and cyclin A2/CDK2 complexes were downregulated. Overall, these findings supported the potential of crebanine as an adjuvant therapy in RCC.
    Preclinical • Journal • PARP Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • CASP7 (Caspase 7) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)